{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-036897","form_type":"8-K","ticker":"RMTI","cik":"0001041024","company_name":"ROCKWELL MEDICAL, INC.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.195978+00:00","generated_at":"2026-06-04T09:30:03.985472+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rockwell Medical posts record 2023 net sales of $83.6M; achieves first-ever adjusted EBITDA profit in Q4","bullets":["Q4 2023 net sales $22.1M (+14% YoY); Q4 adjusted EBITDA $0.5M vs ($0.6M) in Q4 2022, first positive quarter in company history.","Full-year 2023 net sales $83.6M (+15% YoY); gross profit $8.7M (+114% YoY); net loss improved 55% to ($8.4M).","2024 guidance: net product sales $84-88M (5-10% growth), gross margin 14-16%, and full-year adjusted EBITDA $0-0.5M.","Amended Innovatus loan: interest rate reduced, maturity extended to Jan 2029; interest-only payments for 30-36 months.","Acquired Evoqua hemodialysis concentrates assets in July 2023; became leading US liquid bicarbonate supplier."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-036897","json":"https://secwatch.observer/filing/0001104659-24-036897.json","markdown":"https://secwatch.observer/filing/0001104659-24-036897.md","text":"https://secwatch.observer/filing/0001104659-24-036897.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1041024/000110465924036897/0001104659-24-036897-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1041024/000110465924036897/tm249327d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:30:03.985472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d3a364cf7e09b5fba0546c389109d09d2a86c35","claim":"ROCKWELL MEDICAL, INC. updated its the three months and twelve months ended December 31, 2023 guidance (initiated).","evidence_excerpt":"Rockwell Medical, Inc. (the \"Company\") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide , today announced financial and operational results for the three months and twelve months ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465924036897/0001104659-24-036897-index.htm","confidence":0.75,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months and twelve months ended December 31, 2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}